Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Peripheral Blood Progenitor Cells

Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma

Bone Marrow Transplantation volume 28, pages 137–143 (2001)Cite this article

Abstract

Forty-one patients with multiple myeloma were treated with a novel stem cell mobilisation regimen. The primary end points were adequate stem cell mobilising ability (>1% circulating CD34-positive cells) and collection (⩾4 × 106 CD34-positive cells/kg), and safety. The secondary end point was activity against myeloma. The regimen (d-TEC) consisted of dexamethasone, paclitaxel 200 mg/m2 i.v., etoposide 60 mg/kg i.v., cyclophosphamide 3 g/m2 i.v., and G-CSF 5–10 μg/kg/day i.v. A total of 84 cycles were administered to these 41 individuals. Patient characteristics included a median age of 53 years, a median of five prior chemotherapy cycles, and a median interval of 10 months from diagnosis of myeloma to first cycle of d-TEC. Seventy-five percent of the patients had stage II or III disease, 50% had received carmustine and/or melphalan previously, and 25% had received prior radiation therapy. Eighty-eight percent of patients mobilised adequately after the first cycle of d-TEC and 91% mobilized adequately after the second cycle. An adequate number of stem cells were collected in 32 patients. Of the remaining nine patients, three mobilised, but stem cells were not collected, two mobilised but stem cell collection was <4 × 106 CD34-positive cells/kg, three did not mobilise, and one died of disease progression. Major toxicities included pancytopenia, alopecia, fever and stomatitis. One patient died from multi-organ failure and progressive disease. Fifty percent of evaluable patients demonstrated a partial response and 28.6% of patients had a minor response. This novel dose-intense regimen was safe, capable of stem cell mobilisation and collection, even in heavily pre-treated patients, and active against the underlying myeloma. Bone Marrow Transplantation (2001) 28, 137–143.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial Blood 1998 92: 3131–3136

    CAS  Google Scholar 

  2. Barlogie B, Jaganath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65

    CAS  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  4. Boiron J-M, Marit G, Faberes C et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF) Bone Marrow Transplant 1993 12: 49–55

    CAS  Google Scholar 

  5. Tricot G, Jaganath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596

    CAS  Google Scholar 

  6. Demuynck H, Delforge M, Verhoef G et al. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF Br J Haematol 1995 90: 384–392

    Article  CAS  Google Scholar 

  7. Kelsey SM, Hazel D, Murrell C, Newland AC . GM-CSF for peripheral blood stem cell harvest in myeloma (letter) Br J Haematol 1996 92: 505

    Article  CAS  Google Scholar 

  8. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections Br J Haematol 1996 93: 142–145

    Article  CAS  Google Scholar 

  9. Goldschmidt H, Hegenbart U, Haas R, Hunstein W . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma Bone Marrow Transplant 1996 17: 691–697

    CAS  Google Scholar 

  10. Demirer T, Buckner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma Bone Marrow Transplant 1996 17: 937–941

    CAS  PubMed  Google Scholar 

  11. Martinez E, Sureda A, De Dalmases C et al. Mobilization of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma Bone Marrow Transplant 1996 18: 1–7

    CAS  PubMed  Google Scholar 

  12. Long GD, Chao NJ, Hu WW et al. High-dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma Cancer 1996 78: 2502–2509

    Article  CAS  Google Scholar 

  13. Alegre A, Tomas JF, Martinez-Chamorro C et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone Bone Marrow Transplant 1997 20: 211–217

    Article  CAS  Google Scholar 

  14. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma Br J Haematol 1997 98: 736–744

    Article  CAS  Google Scholar 

  15. Omede P, Tarella C, Palumbo A et al. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses Br J Haematol 1997 99: 685–691

    Article  CAS  Google Scholar 

  16. Schiller G, Vescio R, Freytes C et al. Autologous CD34-selected blood progenitor cell transplants for advanced multiple myeloma Bone Marrow Transplant 1998 21: 141–145

    Article  CAS  Google Scholar 

  17. Desikan KR, Barlogie B, Jaganath S et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma J Clin Oncol 1998 16: 1547–1553

    Article  CAS  Google Scholar 

  18. Marit G, Thiessard F, Faberes C et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study Leukemia 1998 12: 1447–1456

    Article  CAS  Google Scholar 

  19. Abonour R, Scott KM, Kunkel LA et al. Autologous transplantation of mobilized peripheral blood CD34+ cells by immunomagnetic procedures in patients with multiple myeloma Bone Marrow Transplant 1998 22: 957–963

    Article  CAS  Google Scholar 

  20. Gupta D, Bybee A, Cooke F et al. CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome Br J Haematol 1999 104: 166–177

    Article  CAS  Google Scholar 

  21. Vescio R, Schiller G, Stewart AK et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma Blood 1999 93: 1858–1868

    CAS  Google Scholar 

  22. Facon T, Harousseau JL, Maloisel F et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial Blood 1999 94: 1218–1225

    CAS  PubMed  Google Scholar 

  23. Gandhi M, Jestice H, Scott M et al. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis Bone Marrow Transplant 1999 24: 369–375

    Article  CAS  Google Scholar 

  24. Abraham R, Chen C, Tsang R et al. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma Bone Marrow Transplant 1999 24: 1291–1297

    Article  CAS  Google Scholar 

  25. Boccadoro M, Omede P, Dominietto A et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support Bone Marrow Transplant 2000 25: 25–29

    Article  CAS  Google Scholar 

  26. Dyson PG, Horvath N, Joshua D et al. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma Bone Marrow Transplant 2000 25: 1175–1184

    Article  CAS  Google Scholar 

  27. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation Br J Haematol 1994 87: 825–831

    Article  CAS  Google Scholar 

  28. Mahe B, Milpied N, Hermouet S et al. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma Br J Haematol 1996 92: 263–268

    Article  CAS  Google Scholar 

  29. Kobbe G, Sohngen D, Bauser U et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma Ann Hematol 1999 78: 456–462

    Article  CAS  Google Scholar 

  30. Cook G, Marinaki P, Farrell E et al. Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy Leukemia 1997 11: (Suppl. 5) S35–S40

    CAS  PubMed  Google Scholar 

  31. Engelhardt M, Winkler J, Waller J et al. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF Bone Marrow Transplant 1997 19: 529–537

    Article  CAS  Google Scholar 

  32. Kiel K, Cremer FW, Ehrbrecht E et al. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield Bone Marrow Transplant 1998 21: 1109–1115

    Article  CAS  Google Scholar 

  33. Weaver CH, Zhen B, Schwartzberg LS et al. Phase I–II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma Bone Marrow Transplant 1998 22: 245–251

    Article  CAS  Google Scholar 

  34. Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens Bone Marrow Transplant 1999 23: 111–117

    Article  CAS  Google Scholar 

  35. Lokhorst HM, Sonneveld P, Cornelissen JJ et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma Bone Marrow Transplant 1999 23: 317–322

    Article  CAS  Google Scholar 

  36. Rajkumar SV, Fonseca R, Lacy NQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma Bone Marrow Transplant 1999 23: 1267–1272

    Article  CAS  Google Scholar 

  37. Lefrere F, Makke J, Fermand J et al. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma Bone Marrow Transplant 1999 24: 463–466

    Article  CAS  Google Scholar 

  38. Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L et al. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization Bone Marrow Transplant 2000 25: 1141–1146

    Article  CAS  Google Scholar 

  39. Cremer FW, Kiel K, Wallmeier M et al. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone Exp Hematol 1998 26: 969–975

    CAS  PubMed  Google Scholar 

  40. Bilgrami S, Feingold JM, Bona RD et al. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer Bone Marrow Transplant 2000 25: 123–130

    Article  CAS  Google Scholar 

  41. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment Cancer 1981 47: 207–214

    Article  CAS  Google Scholar 

  42. Siena S, Bregni M, Belli N et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients Blood 1991 77: 400–409

    CAS  Google Scholar 

  43. Gregory CJ, Eaves AC . Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses Blood 1977 49: 855–864

    CAS  Google Scholar 

  44. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. On behalf of the Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant), Chronic Leukaemia Working Party and the Myeloma Working Committee of the IBMTR (International Bone Marrow Transplant Registry) and ABMTR (Autologous Blood and Marrow Transplant Registry) Br J Haematol 1998 102: 1115–1123

    Article  CAS  Google Scholar 

  45. Dimopoulos MA, Arbuck S, Huber M et al. Primary therapy of multiple myeloma with paclitaxel (taxol) Ann Oncol 1994 5: 757–759

    Article  CAS  Google Scholar 

  46. Demirer T, Rowley S, Buckner CD et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer J Clin Oncol 1995 13: 1714–1719

    Article  CAS  Google Scholar 

  47. Gockerman JP, Bartolucci AA, Nelson MO et al. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial Cancer Treat Rep 1986 70: 801–802

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Program, University of Connecticut Health Center, Farmington, CT, USA

    S Bilgrami, RD Bona, RL Edwards, Z Li, B Naqvi, A Shaikh, F Furlong, J Fox, J Clive & PJ Tutschka

Authors
  1. S Bilgrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. RD Bona
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. RL Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Z Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Naqvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Shaikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Furlong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Clive
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. PJ Tutschka
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bilgrami, S., Bona, R., Edwards, R. et al. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma. Bone Marrow Transplant 28, 137–143 (2001). https://doi.org/10.1038/sj.bmt.1703126

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703126

Keywords

This article is cited by

Search

Advanced search

Quick links